10 results about "Blood derivatives" patented technology

The present invention pertains to the field of medicine and relates to a bag used for the collection, storage and separation of blood derivatives. The present patent is designed to enable the collection and separation of blood components in a single bag, suitable for generating fractionated bags and blood sample aliquots. This practice eliminates the risk of contamination due to the transfer and / or exposure of the blood products. The invention relates to a bag (1) composed of two superimposed polymeric films (2) and (3) sealed along their perimeter, and provided at its two ends with connectors (4), (5), (6), and (7), and handles (8) and (9), respectively; the bag (1) comprises an hourglass-shaped narrowing (10), formed by two trapezoidal seams (11) and (12) arranged opposite each other; the narrowing (10) has a length of between 6 mm and 15 mm (preferably 10 cm), a width of between 2 cm and 6 cm (preferably 4 cm), and angles (α), (β), (γ), and (δ) of between 10° and 60° (preferably 20°), while two or more demarcation lines (13) and (14) are placed transversely on both faces, on the narrowed region (11).

A microfluidic, chip-based assay device has been developed for measuring physical properties of an analyte (particularly, whole blood or whole blood derivatives). The technologies can be applied to measure clotting times of whole blood or blood derivatives, determine the effects of anticoagulant drugs on the kinetics of clotting / coagulation, as well as evaluate the effect of anticoagulant reversal agents. These technologies can additionally be used to optimize the dosage of anticoagulation drugs and / or their reversal agents. The assay is independent of the presence of anticoagulant; clotting is activated by exposure of the blood sample in the device to a glass (or other negatively charged material such as oxidized silicon) surface, which activates the intrinsic pathway and can be further hastened by the application of shear flow across the activating materials surface. The absence of chemical activating agents and highly controlled and reproducible micro-environment yields a point of care universal clotting assay.

An animal-extract free, blood-free and blood-derivative free culture medium formulation is presented. It is developed for growth of fastidious, hemophilic, anaerobic and capnophilic bacteria as well as semi-fastidious and non-fastidious bacteria. The culture medium comprises (i) enriched basal media, (ii) at least one oxygen scavenging agent, (iii) toxic metabolite adsorbent, (iv) growth factor(s) and (v) an active ingredient. The culture medium further includes pH adjuster(s), vitamin, reducing agents and solvent.

The present invention relates to an animal extract free, blood free and blood derivative free culture medium formulation for growth of fastidious, hemophilic, anaerobic and capnophilic bacteria as well as semi fastidious and non-fastidious bacteria. The culture medium comprises (i) enriched basal media, (ii) at least one oxygen scavenging agent, (iii) toxic metabolite adsorbent, (iv) growth factor(s) and (v) an active ingredient. The culture medium further includes pH adjuster(s), vitamin, reducing agents and solvent.

The utility model discloses a blood derivative taking-out device which comprises a tube body inserted into a centrifugal tube and an upper cover located at the upper end of the tube body and provided with a first sliding groove and a second sliding groove, and a first movable rod and a second movable rod are movably connected into the first sliding groove and the second sliding groove respectively. The first movable rod and the second movable rod downwards penetrate through the upper cover and extend to the lower portion of the pipe body to be connected with a cutting piece, a fixing ring fixedly connected with the inner wall of the pipe body is arranged on the lower portion of the pipe body, and the cutting piece comprises a first cutting plate and a second cutting plate which are hinged to the fixing ring and oppositely arranged. The close sides of the first cutting plate and the second cutting plate are movably connected to the first movable rod and the second movable rod correspondingly. The blood derivative CGF / PRF taking-out process is simple and easy to operate, the blood derivative CGF / PRF cannot be torn, the blood derivative in the tube body does not make contact with the outside, pollution caused by the fact that the blood derivative CGF / PRF makes contact with air is prevented, and the follow-up clinical use effect is guaranteed.

The present invention relates to novel carbohydrate derivatives having activity as mimetics of blood group A and B antigens. The invention also relates to a process for producing said carbohydrate derivatives and to glycoconjugates comprising them bound to a polymeric support. The invention also relates to the use of the glycoconjugates for inhibiting and / or removing anti-A and / or anti-B antibodies from blood and blood derivatives and by-products, and their use, in particular, for avoiding rejection reactions or hemolysis in blood transfusions in subjects receiving organ transplants from incompatible donors.

The present invention relates to a method for diagnosing the risk of non-alcoholic steatohepatitis (NAS) in a human patient with a metabolic disorder, comprising: (i) calculating a non-alcoholic fatty liver disease (NFD) score from the patient's age, body mass index (BMI), aspartate aminotransferase (AST) / alanine aminotransferase (ALT) ratio, platelet count, and hyperglycemic status; and (ii) calculating a non-alcoholic steatohepatitis score (NIS4) for the patient based on the levels of hsa-miR-34a-5p, alpha-2-macroglobulin (A2M), YKL-40, and glycosylated hemoglobin (HbA1c), measured in a blood sample or blood derivative from the patient; and determining the presence or absence of NAS risk in the patient based on these scores. where the NFS test is implemented before or after the NIS4 test.

A microfluidic, chip-based assay device has been developed for measuring the physical properties of an analyte (specifically, whole blood or whole blood derivatives). The technologies can be applied to measure the clotting times of whole blood or blood derivatives, determine the effects of anticoagulant drugs on the kinetics of clotting / coagulation, and evaluate the effect of anticoagulant reversal agents. These technologies can additionally be used to optimize the dosage of anticoagulant drugs and / or their reversal agents.The assay is anticoagulant-independent - clotting is initiated by exposing the blood sample within the device to a glass surface (or other negatively charged material such as oxidized silica), which activates the intrinsic pathway and can be further accelerated by applying shear flow across the surface of the activating materials. The absence of chemical activating agents and a highly controlled and reproducible microenvironment yield a universal point-of-care clotting assay.

The present invention relates to a blood derivative comprising a polyclonal antibody against a pathogen for use in the prevention and / or treatment of airborne diseases caused by said pathogen, characterized in that said blood derivative is administered intranasally.

The present invention relates to new carbohydrate derivatives with activity as mimetics of blood group A and B antigens. The present invention also relates to a method for preparing said carbohydrate derivatives and to a glycoconjugate comprising them bound to a polymeric support. The invention also relates to the use of the glycoconjugates for inhibiting and / or removing anti-A and / or anti-B antibodies from blood and blood derivatives and by-products, and, in particular to their use for avoiding rejection in subjects undergoing in organ transplant or haemolytic reactions in blood transfusions from incompatible donors.